Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country
Authors:
- 1 November 2021
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21 (11) , e853-e864
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Compassionate Use of Remdesivir for Patients with Severe Covid-19New England Journal of Medicine, 2020
- Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatmentEuropean Journal of Cancer, 2020
- Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort studyThe Lancet Infectious Diseases, 2020
- Epidemiology of COVID-19 Among Children in ChinaPediatrics, 2020
- The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19The Lancet Oncology, 2020
- Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort studyBMJ, 2020
- Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adultsActa Paediatrica, 2020
- Clinical strategies for treating pediatric cancer during the outbreak of 2019 novel coronavirus infectionPediatric Blood & Cancer, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release SyndromeThe Oncologist, 2018